Successful Steroid Therapy in a Child with Suspected Autoimmune Hepatitis
Main Article Content
Abstract
Introduction: Autoimmune Hepatitis (AIH) is an unexplained cause of chronic and progressive liver inflammation. The incidence of AIH is about 4.82/per 100,000 people in Korea, but based on global research the incidence is increasing and it should be taken more seriously. Laboratory and imaging tests were performed which led to the diagnosis of AIH but to diagnose AIH is difficult. Steroid therapy is an option for this patient by considering the side effects that are well-monitored. A favourable outcome was shown and this report is expected to highlight the importance of early diagnosis and treatment in AIH cases.
Case presentation: A 6-year-old, 5-month-old girl presented to Dr. Soetomo General Academic Hospital, Surabaya with jaundice for 2 weeks. She had been unable to walk for the past 1 month due to pain in both legs, nausea and vomiting, anorexia, right-sided abdominal pain, and an enlarged abdomen. She has had a history of fever for the past 1 month. Laboratory parameters showed cholestasis, abnormal liver function test (aspartate aminotransferase (AST) 1406 U/L, alanine aminotransferase (ALT) 1392 U/L, and prolonged coagulation factor), and positive antinuclear antibody (ANA) test (79.10 AU/mL). Hepatitis markers were negative. Liver biopsy and autoantibodies examination (LKM and SMA) was not done due to limited facilities. Hepatitis, cholecystitis, and ascites were noted on abdominal ultrasonography. Ascites and cholecystitis were seen on an abdominal CT scan. Steroid therapy was administered and there was improvement in clinical condition and laboratory results following two weeks duration of treatment.
Conclusion: This case report illustrates that steroid treatment for a child with AIH results in a good improvement and provides achievement of treatment goals following existing guidelines. The use of steroid therapy in suspected cases of AIH, without further diagnostic modalities, may be of value in the prevention of further liver damage, especially in healthcare settings with limited resources.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Linzay CD, Sharma B, Pandit S. Autoimmune Hepatitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Jun 20]. Available from:
http://www.ncbi.nlm.nih.gov/books/NBK459186/
II. Mieli‐Vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A, et al. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. J pediatr gastroenterol nutr. 2018 Feb;66(2):345–60.
III. Kim BH, Choi HY, Ki M, Kim KA, Jang ES, Jeong SH. Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea. Yu ML, editor. PLoS ONE. 2017 Aug 3;12(8):e0182391.
IV. Tunio NA, Mansoor E, Sheriff MZ, Cooper GS, Sclair SN, Cohen SM. Epidemiology of Autoimmune Hepatitis (AIH) in the United States Between 2014 and 2019: A Population-based National Study. Journal of Clinical Gastroenterology. 2021 Nov;55(10):903–10.
V. Hahn JW, Yang HR, Moon JS, Chang JY, Lee K, Kim GA, et al. Global incidence and prevalence of autoimmune hepatitis, 1970–2022: a systematic review and meta-analysis. eClinicalMedicine. 2023 Nov;65:102280.
VI. Mercado LA, Gil-Lopez F, Chirila RM, Harnois DM. Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview. Diagnostics. 2024 Feb 9;14(4):382.
VII. Ansari Q, Sawant V, Kondekar A. Different presentation of autoimmune hepatitis in children: Case series. J Family Med Prim Care. 2023;12(2):406.
VIII. Altamimi E, Al Omari D, Obeidat H, Barham K. Retrospective, single-center analysis of autoimmune hepatitis in Jordanian children: clinical features, treatments, and outcomes. BMC Pediatr. 2024 Feb 8;24(1):102.
IX. Chung Y, Rahim MN, Graham JJ, Zen Y, Heneghan MA. An update on the pharmacological management of autoimmune hepatitis. Expert Opinion on Pharmacotherapy. 2021 Jul 24;22(11):1475–88.
X. Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D. Autoimmmune hepatitis. Cell Mol Immunol. 2022 Feb;19(2):158–76.
XI. De Luca F, Shoenfeld Y. The microbiome in autoimmune diseases. Clinical and Experimental Immunology. 2018 Dec 19;195(1):74–85.
XII. Sirbe C, Simu G, Szabo I, Grama A, Pop TL. Pathogenesis of Autoimmune Hepatitis—Cellular and Molecular Mechanisms. IJMS. 2021 Dec 17;22(24):13578.
XIII. Lerner A, Matthias T. Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmunity Reviews. 2015 Jun;14(6):479–89.
XIV. Mazzucca CB, Raineri D, Cappellano G, Chiocchetti A. How to Tackle the Relationship between Autoimmune Diseases and Diet: Well Begun Is Half-Done. Nutrients. 2021 Nov 5;13(11):3956.
XV. Schaefer TJ, John S. Acute Hepatitis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Jun 20]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK551570/
XVI. Aljumah AA, Al-Ashgar H, Fallatah H, Albenmousa A. Acute onset autoimmune hepatitis: Clinical presentation and treatment outcomes. Annals of Hepatology. 2019 May;18(3):439–44.
XVII. Zheng L, Liu Y, Shang Y, Han Z, Han Y. Clinical characteristics and treatment outcomes of acute severe autoimmune hepatitis. BMC Gastroenterol. 2021 Dec;21(1):93.
XVIII. Fernandes B. Rheumatologic manifestations of hepatic diseases. aog [Internet]. 2019 [cited 2024 Jun 21]; Available from:
http://www.annalsgastro.gr/files/journals/1/earlyview/2019/ev-05-2019-10-AG4472-0386.pdf
XIX. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Liver involvement in patients with systemic autoimmune diseases. Maedica (Bucur). 2013 Sep;8(4):394–7.
XX. Biewenga M, Inderson A, Tushuizen ME, Crobach ASLP, Van Hoek B. Early Predictors of Short‐Term Prognosis in Acute and Acute Severe Autoimmune Hepatitis. Liver Transpl. 2020 Dec;26(12):1573–81.
XXI. Dong Y, Potthoff A, Klinger C, Barreiros AP, Pietrawski D, Dietrich CF. Ultrasound findings in autoimmune hepatitis. WJG. 2018 Apr 21;24(15):1583–90.
XXII. Schreiber-Dietrich D, Pohl M, Zentrum der Kinderheilkunde Abteilung für Kindergastroenterologie und Mukoviszidose, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany, Cui XW, Innere Medizin 2, Caritas Krankenhaus Bad Mergentheim, Bad Mergentheim, Germany, Braden B, et al. Perihepatic lymphadenectomy in children with chronic viral hepatitis. J Ultrason. 2015 Jul 20;61:137–50.
XXIII. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020 Aug;72(2):671–722.
XXIV. Lohse AW, Sebode M, Jørgensen MH, Ytting H, Karlsen TH, Kelly D, et al. Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. Journal of Hepatology. 2020 Dec;73(6):1496–506.
XXV. Ramamoorthy S, Cidlowski JA. Corticosteroids. Rheumatic Disease Clinics of North America. 2016 Feb;42(1):15–31.
XXVI. Libert C, Dejager L. How Steroids Steer T Cells. Cell Reports. 2014 May;7(4):938–9.
XXVII. Longhi MS, Mieli-Vergani G, Vergani D. Regulatory T cells in autoimmune hepatitis: an updated overview. Journal of Autoimmunity. 2021 May;119:102619.